Verve Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verve Therapeutics, Inc.
Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.